Tumor Fighter

Researchers from the Perelman School of Medicine have found that the effectiveness of CAR T-cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology. “We’ve discovered in preclinical models that CD5 deletion greatly enhances the function of CAR-T cells against multiple cancers,” Marco Ruella says.